Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Covington
Accenture
McKinsey
Chubb
Boehringer Ingelheim

Generated: August 18, 2019

DrugPatentWatch Database Preview

Erdafitinib - Generic Drug Details

  Try a free trial


See Plans and Pricing

« Back to Dashboard

What are the generic sources for erdafitinib and what is the scope of erdafitinib freedom to operate?

Erdafitinib is the generic ingredient in one branded drug marketed by Janssen Biotech and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Erdafitinib has seventy-seven patent family members in thirty-seven countries.

One supplier is listed for this compound.

Summary for erdafitinib
International Patents:77
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 29
Clinical Trials: 12
Patent Applications: 24
DailyMed Link:erdafitinib at DailyMed
Synonyms for erdafitinib
1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-
1346242-81-6
5SF
890E37NHMV
AC-30222
AK547250
AS-35040
BCP20346
CHEMBL3545376
compound 4 [WO2011135376]
CS-4988
D10927
DB12147
Erdafitinib (JNJ-42756493)
Erdafitinib (USAN/INN)
Erdafitinib [USAN:INN]
Erdafitinib,JNJ-42756493 ,JNJ 42756493 ,JNJ42756493
Erdafitinib; JNJ-42756493
EX-A2564
GTPL9039
HY-18708
JNJ 42756493
JNJ-42756493
JNJ-42756493 (Erdafitinib)
jnj-42756493-erdafitinib
JNJ42756493
MFCD28502040
N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-N-propan-2-ylethane-1,2-diamine
s8401
SB16854
SCHEMBL2583760
UNII-890E37NHMV
ZINC168520308

US Patents and Regulatory Information for erdafitinib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Biotech BALVERSA erdafitinib TABLET;ORAL 212018-001 Apr 12, 2019 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Janssen Biotech BALVERSA erdafitinib TABLET;ORAL 212018-003 Apr 12, 2019 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Janssen Biotech BALVERSA erdafitinib TABLET;ORAL 212018-001 Apr 12, 2019 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Janssen Biotech BALVERSA erdafitinib TABLET;ORAL 212018-002 Apr 12, 2019 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Janssen Biotech BALVERSA erdafitinib TABLET;ORAL 212018-003 Apr 12, 2019 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Chinese Patent Office
Citi
Fish and Richardson
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.